With a market capitalization (market cap) of $1.1B — a measure of how much the company is worth — Savara Inc. is the 2526th most valuable company in Healthcare as of August 18, 2026. Shares trade at $5.37, up 0.00% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Visit websiteAs of August 18, 2026, Savara Inc. (SVRA) is worth $1.1B — this is its market capitalization, the total value of all its outstanding shares.
Savara Inc.’s market cap is $1.1B, which ranks it #2526 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Savara Inc. (SVRA) shares trade at $5.37, up 0.00% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025